Pharma Pulse 4/23/25: Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation, Trump Assessing Slashing US Drug Prices to International Levels

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron and Roche are investing a combined $53 billion over the next decade to expand US manufacturing and R&D infrastructure—spanning biologics, gene therapy, AI-driven research, and next-gen therapeutics—in response to rising global demand and potential US pharmaceutical tariffs, with Regeneron focusing on biologics and job creation through partnerships and facility growth, and Roche targeting pharmaceutical, diagnostics, and metabolic innovation across multiple states.

Trump assessing slashing US drug prices to international levels - Reuters

The Trump administration is considering tying US drug prices to the lower rates paid in other developed countries through international reference pricing—a move that has resurfaced as a key concern for the pharmaceutical industry and could be implemented via Medicare negotiations, despite legal setbacks during Trump’s first term and the absence of explicit mention in recent executive orders.

Former Neumora CEO to lead Galapagos spinout

Galapagos has appointed former Neumora CEO Henry Gosebruch to lead a $2.5 billion spinout focused on building a pipeline of cancer, virology, and immunology drugs through strategic deals, as part of a broader company restructuring that will also see CEO Paul Stoffels retire within a year while Galapagos refocuses on cell therapies for hard-to-treat cancers.

Supreme Court seems likely to uphold ACA preventive services mandate

The Supreme Court appears likely to uphold the Affordable Care Act’s mandate requiring insurers to cover certain preventive services at no cost, with justices expressing skepticism toward arguments that the federal task force recommending these services is unconstitutional.

Keeping Up With The Growing Number of Treatments for Breast Cancer

Breast cancer, the most common cancer in women, is highly treatable—especially when detected early—with personalized therapies based on tumor biology, and pharmacists play a vital role in optimizing treatment, managing side effects, and supporting patient care.